Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric tbo-filgrastim study in solid tumors with chemotherapy-induced neutropenia
2014-001772-55Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Safety and tolerability of tbo-filgrastim. Started Nov 2014; status: completed.
02
Drugs
filgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2014-001772-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001772-55.